A series of bispecific antibodies combining anti-CD47 specificity with anti-PD-L1, -EGFR, -CD19, or -CD20 activity may preserve tumor-specific phagocytosis-stimulating activities while sparing the host cells that do not express the tumor antigen, thus limiting toxicity. This evidence concerns the gene CD47 and neoplasm.